65,437 trials
Secondary Hypogonadism
Primary: 24 Hour Average and Maximum Testosterone Concentration — 262.3; 373.6; 298.3; 322.4 ng/dL — p=0.056
Neuroendocrine Carcinoma
Primary: Objective Response Rate (ORR) — 16; 18; 16 percentage of participants
Spinal Disorder
Primary: Change of Pain Intensity* at Week 8 of Treatment With the Study Drug From Baseline — -1.65 units on a scale — p=<0.05
Pneumonia
Primary: Hospital Acquired Pneumonia Occurrences — 2; 13 participants
Knee Osteoarthritis · Chronic Pain
Primary: Pain Pressure Threshold (PPT) After Intervention.. — 8.82; 6.66 Kgf / cm2
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis — -10.7; -28.9; -31.5; -42.5 percent change — p=0.0000
Lymphoma
Primary: Percentage of Participants Who Experienced a Dose-limiting Toxicity in Phase I of the Study — 0; 0; 0; 0 percentage of participants
Cystic Fibrosis
Primary: Percent Mucociliary Clearance at 60 Minutes — 18.6; 15.4 percentage mucociliary clearance — p=0.62
Multiple Myeloma
Primary: Overall Survival — 65; 58 percentage of participants
Rheumatoid Arthritis
Primary: Percentage of Subjects in Sustained Remission at Week 52 — 15.0; 28.9 percentage of subjects — p=<0.001
Hypoxia
Primary: Plasma Glucose Concentration — 93.8; 95.7; 94.1; 93.3 mg/dl
Neoplasms, Advanced Solid
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0 participants
Hepatitis C
Primary: Sustained Virologic Response (SVR) at 24 Weeks Post Treatment — 6; 3 participants
Pregnancy
Primary: Percentage of Infants With Major Birth Defects in Pregnancies Ending With Live-born Infants — 9.4; 3.5 percentage of participants
Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients
Primary: Percentage of BCCs With Complete and at Least Partial Clinical Clearance — 92; 7; 83; 77 Percentage of BCCs